(Q43202400)

16 November 2017

title

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. (English)

1 reference

16 November 2017

1 reference

1 reference

1 reference

Fred Poordad

0 references

Waldemar Halota

object named as

Waldemar Halota

1 reference

16 November 2017

Uchenna Iloeje

1 reference

16 November 2017

Ting-Tsung Chang

1 reference

16 November 2017

Ching-Lung Lai

1 reference

16 November 2017

Seung Kew Yoon

1 reference

16 November 2017

Samuel S Lee

1 reference

16 November 2017

Henrique Sergio M Coelho

1 reference

16 November 2017

Flair Jose Carrilho

1 reference

16 November 2017

Yves Horsmans

1 reference

16 November 2017

Naoky Tsai

1 reference

16 November 2017

Hui Zhang

1 reference

16 November 2017

Daniel J Tenney

1 reference

16 November 2017

Ricardo Tamez

1 reference

16 November 2017

language of work or name

English

0 references

publication date

1 February 2010

1 reference

16 November 2017

1 reference

16 November 2017

1 reference

16 November 2017

1 reference

16 November 2017

page(s)

422-430

1 reference

16 November 2017

1 reference

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

21 January 2018

1 reference

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update

21 January 2018

1 reference

21 January 2018

1 reference

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

21 January 2018

1 reference

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present

21 January 2018

1 reference

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

21 January 2018

1 reference

Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications

21 January 2018

1 reference

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

21 January 2018

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/HEP.23327

1 reference

16 November 2017

1 reference